SCHEMBL3012425

SCHEMBL3012425

O=S(=O)(c1ccc(F)cc1)C1CCN(c2nc(-c3cccc(Br)c3)cs2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.54
USP2 O75604 1/20 0.54
RECQL P46063 1/20 0.54
HSD17B10 Q99714 1/20 0.54
SMN1; SMN2 Q16637 11/20 0.52
L3MBTL1 Q9Y468 4/20 0.52
ALDH1A1 P00352 4/20 0.52
RAB9A P51151 7/20 0.48
NPC1 O15118 6/20 0.48
MAPK1 P28482 3/20 0.47
MMP2 P08253 1/20 0.47
MMP8 P22894 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
LMNA P02545 2/20 0.46
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
AR P10275 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008228 0.93 SMN1; SMN2 (0.51) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3016646 0.91 RAB9A (0.48) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3011967 0.90 SMN1; SMN2 (0.49) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3000308 0.90 SMN1; SMN2 (0.52) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3016185 0.90 RAB9A (0.49) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3011413 0.89 SMN1; SMN2 (0.46) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3017062 0.88 MAPT (0.56) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3009419 0.88 SMN1; SMN2 (0.60) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3017544 0.88 MAPT (0.54) MAPTUSP2RECQLHSD17B10SMN1; SMN2
SCHEMBL3004071 0.88 SMN1; SMN2 (0.47) MAPTUSP2RECQLHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885USP2 1831/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.